Treatment of obstetric hemorrhage with recombinant activated factor VII (rFVIIa).
Recombinant activated factor VII (rFVIIa, NovoSeven) was used in three patients with massive obstetric hemorrhage due to placenta previa accreta, rupture of the uterus and pre-eclampsia with HELLP. Administration of the drug markedly decreased the bleeding and enabled control of the hemorrhage. rFVIIa seems to be an adjunctive hemostatic measure for the treatment of severe obstetric hemorrhage.
D001803:Blood Transfusion; D002585:Cesarean Section; D036861:Delivery, Obstetric; D004211:Disseminated Intravascular Coagulation / Q000209:etiology / Q000628:therapy; D015942:Factor VIIa / Q000627:therapeutic use*; D005260:Female; D017359:HELLP Syndrome / Q000150:complications; D006801:Humans; D010921:Placenta Accreta / Q000150:complications; D010923:Placenta Previa / Q000150:complications; D006473:Postpartum Hemorrhage / Q000188:drug therapy* / Q000209:etiology / Q000628:therapy; D011225:Pre-Eclampsia / Q000150:complications; D011247:Pregnancy; D011994:Recombinant Proteins / Q000627:therapeutic use; D012769:Shock / Q000209:etiology / Q000628:therapy; D014597:Uterine Rupture / Q000150:complications
D011994:Recombinant Proteins; D015942:Factor VIIa